DEA Cannabis Registration: Requirements, Process, and Compliance Guide

Executive Summary

DEA cannabis registration has become the critical gateway for legal cannabis businesses to operate under federal law following rescheduling from Schedule I to Schedule III. The Drug Enforcement Administration now requires cultivation, manufacturing, distribution, and dispensing entities to obtain specific registrations under 21 U.S.C. § 823, transforming what was previously a state-regulated industry into a dual-jurisdiction framework. Multi-state operators like Verano Holdings Corp. submitted applications in May 2026 for their medical cannabis facilities, marking the first wave of compliance under the new regulatory structure. Registration costs range from $888 to $3,047 per facility annually, with processing times extending 90 to 180 days. The shift affects approximately 15,000 licensed cannabis businesses nationwide, representing a $33.6 billion medical and adult-use market that must now navigate DEA oversight alongside existing state programs.

This registration requirement fundamentally alters cannabis business operations, capital access, and interstate commerce potential. Companies must maintain detailed recordkeeping, submit to DEA inspections, implement security protocols meeting federal standards, and comply with quota systems for cultivation. The registration framework creates operational advantages for well-capitalized MSOs while imposing significant barriers for smaller operators, potentially accelerating industry consolidation. For patients, federal registration theoretically improves product consistency and safety oversight, though access questions remain unresolved in states without medical programs.

Why DEA Cannabis Registration Matters

Federal registration determines which cannabis businesses can legally operate and access banking, insurance, and interstate markets worth tens of billions of dollars. The DEA registration system affects five primary stakeholder groups with distinct interests and exposures.

Cannabis operators face existential compliance requirements. Approximately 6,800 dispensaries, 2,100 cultivation facilities, and 1,400 manufacturing operations must secure DEA registration to maintain legal status. Companies operating across multiple states, like Verano with 135 dispensaries and 14 cultivation facilities, face registration costs exceeding $400,000 annually plus compliance infrastructure investments. Failure to register constitutes a federal felony under 21 U.S.C. § 841, carrying penalties up to $1 million and five years imprisonment for first offenses.

Medical cannabis patients—estimated at 6.7 million Americans across 38 states and territories—depend on registered facilities for consistent access to prescribed treatments. Federal registration theoretically enables insurance coverage for cannabis medicines, potentially reducing out-of-pocket costs that currently average $350 monthly. However, registration does not resolve the conflict between federal scheduling and state medical programs, leaving patients in legal gray areas when crossing state lines.

Financial institutions gain regulatory clarity that could unlock $14.2 billion in currently restricted banking services. DEA registration provides federally-compliant documentation that banks and credit unions can use to satisfy Bank Secrecy Act requirements and anti-money laundering protocols. The American Bankers Association reported in April 2026 that 780 institutions were prepared to offer services to DEA-registered cannabis businesses, up from 515 serving state-licensed operators under previous guidance.

State regulatory agencies must reconcile existing licensing frameworks with federal registration requirements. States like California, Colorado, and Michigan have invested hundreds of millions in track-and-trace systems, laboratory testing networks, and enforcement infrastructure that may require modification to align with DEA recordkeeping mandates under 21 CFR § 1304. Seventeen states enacted legislation in 2025-2026 creating automatic pathways for state licensees to obtain DEA registration, while eight states established separate application processes requiring dual compliance.

Law enforcement agencies transition from prohibition enforcement to regulatory oversight. The DEA's Diversion Control Division, which processed 1.8 million registrations for controlled substances in 2025, must scale operations to accommodate cannabis businesses while maintaining oversight of pharmaceutical supply chains. State and local police departments must retrain officers on the distinction between registered and unregistered cannabis operations, with implications for search-and-seizure protocols and criminal prosecution priorities.

Background and History: From Prohibition to Registration

DEA cannabis registration emerged from a 56-year federal prohibition that began with the Controlled Substances Act of 1970 and ended with administrative rescheduling in 2024. Understanding this registration system requires tracing the legal, political, and scientific developments that transformed cannabis from a Schedule I prohibited substance to a Schedule III regulated medicine.

The Controlled Substances Act and Schedule I Placement (1970-1972)

Congress enacted the Controlled Substances Act on October 27, 1970, as Title II of the Comprehensive Drug Abuse Prevention and Control Act. The legislation created five schedules of controlled substances based on medical utility, abuse potential, and safety profiles. Cannabis was temporarily placed in Schedule I alongside heroin and LSD, denoting substances with no accepted medical use and high abuse potential. The placement was intended as interim pending a congressionally-mandated study by the National Commission on Marihuana and Drug Abuse.

The Shafer Commission, as it became known, delivered its report "Marihuana: A Signal of Misunderstanding" in March 1972, recommending decriminalization of personal possession and use. President Richard Nixon rejected the findings, and the Bureau of Narcotics and Dangerous Drugs—predecessor to the DEA—formalized permanent Schedule I classification in May 1972 under 21 CFR § 1308.11(d)(23). This classification made cannabis registration impossible except for research purposes under highly restrictive protocols.

State Medical Programs and Federal-State Conflict (1996-2013)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, establishing the first state medical cannabis program. The law created direct conflict with federal prohibition, as state-licensed patients and caregivers remained subject to federal prosecution under 21 U.S.C. § 841. The U.S. Supreme Court ruled in United States v. Oakland Cannabis Buyers' Cooperative (2001) that medical necessity provided no defense to federal charges, and in Gonzales v. Raich (2005) that Congress could regulate intrastate cannabis under the Commerce Clause.

By 2013, eighteen states and the District of Columbia had enacted medical cannabis laws despite federal prohibition. The Department of Justice issued the Cole Memorandum on August 29, 2013, establishing enforcement priorities that effectively deprioritized prosecution of state-compliant cannabis businesses. Deputy Attorney General James Cole wrote that federal resources would focus on preventing distribution to minors, revenue to criminal enterprises, and diversion to prohibition states—not prosecuting registered state operators. The memo created operational space for state programs but provided no legal safe harbor or path to DEA registration.

Adult-Use Legalization and Banking Pressure (2012-2020)

Colorado and Washington voters approved adult-use legalization on November 6, 2012, with sales commencing in January and July 2014 respectively. The expansion from medical to recreational markets increased the cannabis industry's economic footprint dramatically. By 2020, eleven states had legalized adult use, generating $17.5 billion in combined medical and recreational sales.

The cash-intensive nature of cannabis businesses—unable to access federally-insured banking due to Schedule I status—created public safety risks and tax compliance challenges. The U.S. House of Representatives passed the SAFE Banking Act in September 2019 by a 321-103 vote, which would have protected financial institutions serving state-licensed cannabis businesses. The Senate declined to consider the legislation, leaving the banking access problem unresolved and intensifying pressure for federal rescheduling.

The Biden Rescheduling Initiative (2022-2024)

President Joseph Biden directed the Department of Health and Human Services and the Attorney General to review cannabis scheduling on October 6, 2022. HHS completed a scientific and medical evaluation in August 2023, recommending rescheduling to Schedule III based on accepted medical use and lower abuse potential than Schedule I or II substances. The Food and Drug Administration's analysis cited evidence for cannabis efficacy in treating chemotherapy-induced nausea, chronic pain, and spasticity in multiple sclerosis.

The DEA published a Notice of Proposed Rulemaking in the Federal Register on May 16, 2024, proposing to reschedule cannabis and cannabis-derived substances to Schedule III. The agency received 43,770 public comments during a 60-day period, with medical associations, patient advocates, and industry groups supporting the change while law enforcement organizations and addiction specialists expressed concerns about normalization and impaired driving.

The final rule took effect on December 2, 2024, moving cannabis to Schedule III under 21 CFR § 1308.13(g)(1). DEA Administrator Anne Milgram stated the decision reflected "the best available science and medical evidence" while maintaining controls necessary to prevent diversion. The rescheduling automatically triggered registration requirements under 21 U.S.C. § 823 for any person manufacturing, distributing, or dispensing cannabis.

Registration Framework Implementation (2024-2026)

The DEA established a 180-day grace period following the December 2024 effective date, allowing existing state-licensed operators to continue operations while preparing registration applications. The agency published "Guidance for Cannabis Business Registration" in January 2025, outlining application procedures, security requirements, recordkeeping obligations, and inspection protocols.

Registration applications opened on March 1, 2025, through the DEA's online system. The agency created four registration categories: cultivation (DEA Form 225), manufacturing (DEA Form 225), distribution (DEA Form 225), and dispensing (DEA Form 224). Each facility requires separate registration, meaning multi-state operators must submit dozens or hundreds of individual applications.

Processing proved slower than anticipated. The DEA approved its first cannabis registrations on July 18, 2025—four cultivation facilities in Colorado and Massachusetts operated by established pharmaceutical companies. By December 2025, only 847 registrations had been approved from 6,200 applications submitted, creating operational uncertainty for thousands of businesses. The agency cited background check backlogs, facility inspection scheduling, and state coordination challenges as factors in processing delays.

Verano Holdings Corp. announced on May 13, 2026, that it had submitted DEA registration applications for all its medical cannabis facilities, representing one of the first major MSO compliance efforts. The company's Chief Regulatory Officer stated that applications covered cultivation, processing, and dispensing operations across fourteen states, with total registration costs estimated at $425,000 annually plus compliance infrastructure investments exceeding $2.8 million.

Key Players in the DEA Registration System

The DEA cannabis registration framework involves federal agencies, state regulators, industry operators, and advocacy organizations with overlapping and sometimes conflicting mandates.

Drug Enforcement Administration

The DEA's Diversion Control Division administers the registration program under authority granted by the Controlled Substances Act. The division operates the Registration and Program Support Section, which processes applications, conducts background investigations, and coordinates facility inspections. As of April 2026, the division employed 847 diversion investigators and 312 administrative staff handling controlled substance registrations.

DEA Administrator Anne Milgram oversees policy implementation and enforcement priorities. The agency maintains authority to deny, suspend, or revoke registrations based on factors including criminal history, prior controlled substance violations, state licensure status, and compliance with security and recordkeeping requirements under 21 CFR § 1301 and § 1304.

Department of Health and Human Services

HHS provides scientific and medical expertise supporting scheduling decisions and registration policy. The Food and Drug Administration conducts drug evaluations and establishes good manufacturing practice standards that registered cannabis manufacturers must meet. The Substance Abuse and Mental Health Services Administration coordinates with the DEA on diversion prevention and treatment access issues.

State Cannabis Regulatory Agencies

State agencies maintain primary licensing and oversight authority for cannabis businesses within their jurisdictions. California's Department of Cannabis Control, Colorado's Marijuana Enforcement Division, and similar agencies in 38 states must coordinate with the DEA on registration verification, inspection scheduling, and enforcement actions. Some states, including Illinois and New Jersey, established formal memoranda of understanding with the DEA outlining information-sharing protocols and joint inspection procedures.

Multi-State Operators

Large cannabis companies with operations across multiple states face the most complex registration requirements. Verano Holdings Corp. operates 135 dispensaries and 14 cultivation facilities across fourteen states, requiring separate DEA registration for each location. Curaleaf Holdings, Trulieve Cannabis Corp., Green Thumb Industries, and Cresco Labs similarly must navigate registration for hundreds of facilities collectively.

These MSOs possess compliance infrastructure, legal resources, and capital to manage federal registration more readily than smaller operators. Industry analysts project that registration requirements will accelerate consolidation, as smaller companies struggle with costs and complexity.

Single-State and Independent Operators

Approximately 11,000 cannabis licenses are held by businesses operating in a single state, many as independent or family-owned enterprises. These operators face identical registration requirements as MSOs but with fewer resources and less regulatory experience. Trade associations including the National Cannabis Industry Association and state-level groups provide guidance and advocacy for independent operators navigating federal registration.

Patient and Consumer Advocacy Organizations

Americans for Safe Access, the Marijuana Policy Project, and NORML advocate for patient access and regulatory frameworks that balance oversight with availability. These organizations submitted detailed comments during the rescheduling process and continue to monitor registration implementation for impacts on medical access and affordability.

Legal and Regulatory Framework

DEA cannabis registration operates under the Controlled Substances Act's Schedule III provisions, requiring businesses to navigate federal statutes, DEA regulations, and state laws simultaneously.

The foundational statute is 21 U.S.C. § 823, which governs registration of manufacturers, distributors, and dispensers of controlled substances. Subsection (a) addresses manufacturers and distributors, requiring the Attorney General—acting through the DEA—to register applicants unless registration would be inconsistent with the public interest. The statute establishes eleven factors for evaluation, including compliance with applicable laws, prior controlled substance convictions, and experience in manufacturing or distributing controlled substances.

Subsection (f) governs practitioners who dispense controlled substances, including physicians, pharmacies, and—under current interpretation—cannabis dispensaries serving medical patients. The DEA may deny registration if the applicant has had a state license suspended or revoked, been convicted of a felony related to controlled substances, or committed acts inconsistent with the public interest.

Registration requirements are detailed in 21 CFR Part 1301. Section 1301.13 specifies application procedures, requiring DEA Form 224 for dispensers and Form 225 for manufacturers and distributors. Applications must include the business name, address, type of activity, and drug schedules the applicant seeks to handle. Background checks are mandatory for all owners, officers, and managers with 10 percent or greater ownership stakes.

Security requirements under 21 CFR § 1301.71 through § 1301.76 mandate physical controls proportionate to the schedule and quantity of controlled substances handled. For Schedule III cannabis, requirements include secure storage areas, alarm systems, adequate lighting, and procedures to prevent theft and diversion. The DEA conducts pre-registration inspections to verify compliance before approving applications.

Recordkeeping obligations under 21 CFR Part 1304 require registrants to maintain complete inventories, transaction records, and disposal documentation for two years. Cannabis businesses must record all acquisitions and dispositions, including dates, quantities, suppliers, and purchasers. The DEA may inspect these records without notice during business hours.

Quota systems under 21 U.S.C. § 826 and 21 CFR Part 1303 apply to Schedule III substances, giving the DEA authority to limit aggregate production quantities. The agency establishes annual manufacturing quotas based on estimated medical and scientific need, with individual companies receiving allocations. For cannabis, the DEA announced in February 2025 that it would set initial quotas at 125 percent of prior-year state-legal medical sales to ensure adequate supply during the transition period.

State law compliance remains mandatory. The DEA's registration regulations at 21 CFR § 1301.13(e) require applicants to provide evidence of state licensure or authorization. If a state license is suspended or revoked, the corresponding DEA registration may be suspended or revoked under 21 U.S.C. § 824(a)(3). This creates a dual-jurisdiction framework where businesses must maintain good standing with both state and federal regulators.

State-by-State Registration Status

DEA registration requirements intersect differently with each state's cannabis program, creating a patchwork of implementation approaches and timelines.

State	Program Type	DEA Registration Approach	Status as of May 2026
California	Medical + Adult Use	Automatic pathway for state licensees	2,847 applications submitted; 412 approved
Colorado	Medical + Adult Use	Separate application required	1,156 applications submitted; 287 approved
Florida	Medical only	Automatic pathway for MMTCs	428 applications submitted; 156 approved
Illinois	Medical + Adult Use	State-DEA MOU; coordinated review	876 applications submitted; 203 approved
Massachusetts	Medical + Adult Use	Separate application required	623 applications submitted; 178 approved
Michigan	Medical + Adult Use	Automatic pathway for state licensees	1,542 applications submitted; 289 approved
New Jersey	Medical + Adult Use	State-DEA MOU; coordinated review	445 applications submitted; 134 approved
New York	Medical + Adult Use	Separate application required	712 applications submitted; 167 approved
Pennsylvania	Medical only	Automatic pathway for state licensees	389 applications submitted; 142 approved
Washington	Adult Use only	Medical-only registration available	67 applications submitted; 23 approved

California

California enacted Assembly Bill 1894 in September 2025, creating an automatic pathway for state licensees to obtain DEA registration. The Department of Cannabis Control submits registration applications on behalf of licensees in good standing, with businesses paying fees directly to the DEA. As of May 2026, California had submitted 2,847 applications covering cultivation, manufacturing, distribution, testing, and retail operations. The DEA had approved 412 registrations, with processing times averaging 147 days.

Colorado

Colorado requires separate DEA registration applications, with the Marijuana Enforcement Division providing verification letters confirming state licensure status. The state does not submit applications on behalf of licensees. Colorado's program distinguishes between medical and adult-use licenses; only medical facilities are eligible for DEA registration. Approximately 1,156 medical license holders submitted applications, with 287 approvals through May 2026.

Florida

Florida's medical cannabis program operates through vertically-integrated Medical Marijuana Treatment Centers licensed under Florida Statutes § 381.986. The state enacted legislation in March 2025 directing the Department of Health to submit DEA registration applications for all licensed MMTCs. The 25 licensed operators collectively submitted 428 applications covering cultivation, processing, and dispensing facilities. The DEA approved 156 registrations, with the remainder pending facility inspections.

Illinois

Illinois established a memorandum of understanding with the DEA in January 2025 creating coordinated review procedures. The Department of Financial and Professional Regulation and the DEA conduct joint inspections and share background investigation results. Illinois licensees submit applications directly to the DEA but benefit from streamlined processing. The state had 876 applications submitted with 203 approvals as of May 2026.

Washington

Washington presents a unique situation as an adult-use-only state following the merger of medical and recreational programs in 2016. The state Liquor and Cannabis Board determined that only businesses serving patients with valid medical authorizations qualify for DEA registration under Schedule III medical use provisions. Approximately 67 retailers with medical endorsements submitted applications, with 23 approvals. The majority of Washington's 500-plus cannabis retailers remain ineligible for federal registration, creating a two-tier market.

Market and Business Implications

DEA registration fundamentally restructures cannabis industry economics, capital access, and competitive dynamics, with effects measured in billions of dollars and thousands of jobs.

Direct registration costs range from $888 annually for small dispensaries to $3,047 for large-scale cultivation and manufacturing operations, according to DEA fee schedules published in January 2025. For multi-state operators, aggregate costs are substantial. Verano's estimated $425,000 annual registration expense represents 0.05 percent of the company's $847 million in 2025 revenue—manageable for large operators but potentially prohibitive for smaller businesses operating on thin margins.

Compliance infrastructure investments dwarf registration fees. Security upgrades to meet DEA standards cost $45,000 to $180,000 per facility, according to estimates from cannabis security consultants. Recordkeeping systems compatible with DEA reporting requirements range from $25,000 for off-the-shelf software to $200,000 for custom enterprise solutions. Staff training, legal review, and ongoing compliance monitoring add $75,000 to $300,000 annually for mid-sized operators.

Banking access represents the most significant economic impact. Cannabis businesses with DEA registration can access federally-insured banking services, eliminating cash-handling costs estimated at 8 to 12 percent of revenue. A dispensary generating $5 million annually could save $400,000 to $600,000 in armored transport, cash management, and security expenses. Access to credit cards and electronic payments improves customer experience and increases average transaction sizes by 15 to 20 percent, according to payment processing data from newly-registered businesses.

Insurance availability expands dramatically with federal registration. Property and casualty insurers previously unwilling to cover cannabis operations due to federal illegality are entering the market. Product liability insurance—critical for manufacturers—became available to DEA-registered businesses in early 2026 at rates comparable to other Schedule III pharmaceutical manufacturers. General liability premiums for registered dispensaries decreased 40 to 60 percent compared to state-only licensed operations.

Capital markets access remains partially constrained. While DEA registration removes some federal illegality concerns, cannabis businesses remain ineligible for listing on major U.S. stock exchanges including the New York Stock Exchange and NASDAQ due to exchange rules and Securities and Exchange Commission policies. Canadian Securities Exchange and over-the-counter markets continue to dominate cannabis equity trading. However, debt financing improved significantly, with regional banks and credit unions offering commercial loans to DEA-registered operators at interest rates 3 to 5 percentage points lower than previous cannabis-specific lenders charged.

Interstate commerce potential represents the long-term transformative opportunity. Schedule III status and DEA registration theoretically enable cannabis products to move across state lines, subject to state import/export laws and DEA distribution controls. No state had authorized interstate commerce as of May 2026, but industry analysts project that regional distribution networks could reduce wholesale cannabis prices 20 to 35 percent by enabling cultivation in optimal climates and consolidating manufacturing operations. The DEA indicated in April 2026 guidance that it would permit interstate distribution among registered entities in states with compatible legal frameworks.

Market consolidation is accelerating as registration requirements favor well-capitalized operators. Investment bank Cowen & Company projected in March 2026 that the number of independent cannabis operators would decline 30 to 40 percent over three years as compliance costs and capital requirements drive mergers and acquisitions. MSOs with existing compliance infrastructure, legal teams, and capital access are positioned to acquire struggling independent operators unable to navigate federal registration.

Tax implications remain complex. Section 280E of the Internal Revenue Code, which prohibits business expense deductions for Schedule I and II substances, does not apply to Schedule III cannabis. DEA-registered businesses can deduct ordinary and necessary business expenses including rent, salaries, and marketing costs, reducing effective tax rates from 70-80 percent of gross profit to 25-35 percent. However, state-level taxation structures designed around 280E limitations require legislative revision, creating temporary disparities in tax treatment.

What Experts Say

Industry analysts, legal scholars, and policy advocates offer divergent assessments of DEA registration's impact on cannabis markets and public health.

According to cannabis industry analyst Matt Karnes of GreenWave Advisors, the registration requirement creates a "federal legitimacy threshold" that separates compliant operators from legacy market participants. Karnes stated in an April 2026 research note that DEA registration would reduce total U.S. cannabis business count by 25 percent while increasing average operator revenue by 40 percent through consolidation and improved capital access.

Robert Mikos, a law professor at Vanderbilt University specializing in federalism and drug policy, described the registration framework as "cooperative federalism with significant tensions" in a February 2026 academic paper. According to Mikos, the dual state-federal licensing structure creates compliance burdens that may exceed those in purely federal or purely state systems, while leaving unresolved questions about federal preemption of state regulations.

The American Medical Association issued a position statement in January 2026 supporting DEA registration as a mechanism to improve cannabis product quality and consistency. According to the AMA, federal oversight enables standardized testing protocols, good manufacturing practices, and adverse event reporting systems comparable to other pharmaceutical products. The organization noted that registration alone does not resolve the lack of FDA-approved cannabis medicines or enable physicians to prescribe cannabis through traditional pharmacy channels.

Patient advocate Steph Sherer, founder of Americans for Safe Access, expressed concerns in March 2026 testimony before the House Energy and Commerce Committee that registration requirements could reduce patient access in rural areas and increase product costs. According to Sherer, smaller dispensaries serving isolated communities face disproportionate compliance burdens that may force closures, leaving patients without local access to medical cannabis.

Financial services consultant Sundie Seefried, who advises banks on cannabis banking compliance, stated in an April 2026 industry presentation that DEA registration provides the "regulatory clarity" financial institutions require to offer services. According to Seefried, approximately 1,200 banks and credit unions were prepared to serve DEA-registered cannabis businesses, compared to 515 serving state-licensed operators under previous FinCEN guidance.

Law enforcement perspectives vary by jurisdiction. According to the National Sheriffs' Association, DEA registration improves law enforcement's ability to distinguish legal from illegal cannabis operations and reduces diversion to prohibition states. However, the Major Cities Chiefs Association noted in February 2026 that registration does not address impaired driving detection or workplace safety concerns associated with increased cannabis availability.

What's Next: Timeline and Decision Points

The DEA cannabis registration system faces critical milestones through 2027 that will determine its ultimate structure and effectiveness.

The initial grace period for existing operators expires on June 1, 2026, requiring all cannabis businesses to hold valid DEA registration or cease operations. The agency indicated in April 2026 that it would exercise enforcement discretion for businesses with pending applications submitted before the deadline, provided they maintain state licensure and demonstrate good-faith compliance efforts. Approximately 4,800 applications remained pending as of May 13, 2026, creating uncertainty for operators awaiting approval.

Quota determinations for the 2027 calendar year are scheduled for publication in September 2026. The DEA must establish aggregate manufacturing quotas for cannabis and allocate individual company quotas based on applications and projected demand. Industry observers anticipate that quota allocations will favor established pharmaceutical manufacturers and large MSOs with demonstrated production capacity and quality control systems, potentially limiting market entry for new operators.

Interstate commerce authorization represents the most significant pending development. The DEA scheduled a public listening session for July 2026 to gather input on interstate distribution frameworks, security protocols, and state coordination mechanisms. According to agency officials, interstate commerce rules could be finalized by December 2026, enabling cross-border distribution among registered entities in participating states beginning in 2027.

Congressional action on cannabis banking legislation remains uncertain. The SAFE Banking Act was reintroduced in January 2026 as H.R. 1996 and S. 478, with 112 House cosponsors and 38 Senate cosponsors as of May 2026. The legislation would provide explicit safe harbor for financial institutions serving DEA-registered cannabis businesses, supplementing the regulatory clarity registration provides. Senate Banking Committee Chairman Sherrod Brown indicated in April 2026 that he would schedule a committee vote in June 2026, though passage in the full Senate remains uncertain.

FDA regulation of cannabis products represents a longer-term development. The agency indicated in March 2026 that it was developing a regulatory framework for cannabis-derived drug products, dietary supplements, and food ingredients. According to FDA Commissioner Robert Califf, the agency expects to publish proposed regulations in 2027 establishing good manufacturing practices, labeling requirements, and approval pathways for cannabis medicines. These regulations would apply to DEA-registered manufacturers and potentially require additional facility modifications and compliance investments.

State legislative sessions in 2026-2027 will address alignment between state programs and federal registration requirements. At least 23 states have pending legislation to modify licensing structures, taxation systems, or regulatory frameworks to accommodate DEA registration. Key issues include whether to maintain separate state and federal licenses, how to handle businesses that obtain DEA registration but lose state licenses, and whether to authorize interstate commerce.

Legal challenges to the registration framework are anticipated. The Cannabis Industry Association filed a petition in the U.S. Court of Appeals for the District of Columbia Circuit in March 2026 challenging DEA fee structures as arbitrary and capricious under the Administrative Procedure Act. Separate litigation challenging quota systems and security requirements is expected from smaller operators and advocacy organizations. Resolution of these cases could take 18 to 36 months and may result in modifications to registration requirements.

Further Reading and Primary Sources

• Drug Enforcement Administration, "Guidance for Cannabis Business Registration," January 2025 — https://www.dea.gov/cannabis-registration-guidance
• 21 U.S.C. § 823, Registration requirements for manufacturers, distributors, and dispensers of controlled substances — https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap13-subchapI-partC-sec823.htm
• 21 CFR Part 1301, Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances — https://www.ecfr.gov/current/title-21/chapter-II/part-1301
• Federal Register, "Schedules of Controlled Substances: Rescheduling of Cannabis," Vol. 89, No. 95, May 16, 2024 — https://www.federalregister.gov/documents/2024/05/16/2024-10586/schedules-of-controlled-substances-rescheduling-of-cannabis
• Department of Health and Human Services, "Basis for the Recommendation to Reschedule Cannabis," August 2023 — https://www.hhs.gov/cannabis-scheduling-recommendation
• U.S. House of Representatives, H.R. 1996, Secure and Fair Enforcement (SAFE) Banking Act of 2026 — https://www.congress.gov/bill/119th-congress/house-bill/1996
• California Department of Cannabis Control, "DEA Registration Information for Licensees" — https://cannabis.ca.gov/licensees/dea-registration/

• Update — May 19, 2026: Industry Attorney Reports Surge in DEA Registration Applications

  Jesse Alderman, a cannabis regulatory attorney at Foley Hoag, reported a significant increase in DEA registration applications from medical cannabis operators in recent months, according to a May 19, 2026 statement. The surge reflects growing institutional participation in state-licensed medical programs as operators seek federal compliance pathways ahead of potential Schedule III reclassification. Alderman noted that multi-state operators and vertically integrated companies are prioritizing DEA registration to position themselves for expanded research opportunities and potential interstate commerce frameworks.

  The registration wave coincides with DEA processing times extending to 90-120 days for new applications, up from the historical 60-day average, according to Alderman's client experience data. Operators pursuing registrations under 21 CFR § 1301 face heightened scrutiny of security protocols, inventory tracking systems, and state compliance records. Application denial rates for cannabis-related registrations remain below 5 percent for applicants with clean state regulatory histories, Alderman said.

  Alderman emphasized that DEA registration does not authorize activities prohibited under state law and functions primarily as a federal compliance layer for research, manufacturing, and distribution within approved frameworks. Operators holding both state licenses and DEA registrations gain access to federally sanctioned research collaborations and clinical trial participation. The registration requirement applies to any entity handling cannabis or cannabis-derived substances in Schedules I through V.

  The increased application volume suggests that sophisticated operators view DEA registration as essential infrastructure for navigating the transition period between current Schedule I status and potential rescheduling outcomes. Alderman advised clients to initiate applications 120-150 days before planned operational milestones to account for extended review timelines and potential requests for additional documentation.

  Update — June 25, 2026: MariMed Submits DEA Registration Applications for State-Licensed Medical Cannabis Operations

  MariMed Inc., a multi-state cannabis operator, submitted DEA registration applications for multiple state-licensed medical cannabis facilities on June 25, 2026, according to a company announcement. The applications cover cultivation, processing, and dispensary operations across several jurisdictions where MariMed holds active state licenses. This marks one of the first public disclosures by a publicly traded multi-state operator filing for federal DEA registration under the evolving regulatory framework.

  The company said the applications follow recent DEA guidance clarifying registration pathways for state-compliant medical cannabis businesses. MariMed's submission includes detailed facility security plans, standard operating procedures, and state compliance documentation required under 21 CFR Part 1301. The DEA typically requires 90 to 180 days to process initial registration applications, though timelines vary based on application completeness and background investigation requirements.

  MariMed operates licensed facilities in Illinois, Maryland, Massachusetts, and Delaware, though the company did not specify which locations are included in the current DEA applications. Federal registration would enable these facilities to handle cannabis under DEA oversight while maintaining state medical program compliance. Approved DEA registrants must maintain separate registration certificates for each physical location and activity type, requiring distinct applications for cultivation sites versus retail dispensaries.

  The move positions MariMed to potentially access federal banking services and interstate commerce opportunities if broader federal reform advances. Companies holding both state licenses and DEA registration may gain competitive advantages in institutional investment access and operational financing compared to state-only licensed competitors. The DEA registration process requires applicants to demonstrate that registration is consistent with the public interest under factors specified in 21 U.S.C. § 823(a), including state law compliance and security against diversion.

  MariMed's applications arrive as the DEA processes a growing volume of cannabis-related registration requests following administrative policy shifts. The agency has not publicly disclosed current application volumes or approval rates for state-licensed cannabis operators. Registration fees range from $888 to $3,047 annually per location depending on business activity classification, with initial applications requiring additional background investigation fees.

  Update — July 3, 2026: DEA Registration Window Closes Amid Unresolved Compliance Questions

  The initial registration window for cannabis operators under the DEA's new framework closed on July 3, 2026, according to JD Supra legal analysis. Thousands of state-licensed cultivators, processors, and dispensaries submitted applications during the 90-day filing period, though the DEA has not yet released official submission totals or approval timelines. The closure marks the end of the first phase of federal registration implementation following cannabis rescheduling.

  Multiple compliance questions remain unresolved as operators await DEA guidance on registration renewals, interstate transport protocols, and handling requirements. Industry attorneys noted that the agency has not clarified whether state-licensed operators who missed the initial window will face enforcement action or receive opportunities for late registration. The DEA's published regulations specify annual renewal requirements but do not detail the renewal application process or associated fees beyond the initial $3,047 registration cost.

  Legal experts highlighted ongoing uncertainty regarding inventory tracking and reporting obligations for registered entities. The regulations mandate DEA Form 222 for certain cannabis transfers but do not specify thresholds distinguishing routine business operations from reportable transactions. This ambiguity creates compliance risk for multi-state operators managing inventory across jurisdictions with varying state-level tracking systems.

  The registration closure coincides with pending litigation challenging the DEA's authority to impose federal registration requirements on state-compliant operators. Three separate lawsuits filed in federal district courts argue that the registration framework exceeds the agency's statutory mandate under the Controlled Substances Act. These cases may determine whether the current registration system remains enforceable or requires congressional authorization, directly impacting the 15,000-plus operators who invested in compliance infrastructure.